Simply Wall St
4 min read
LifeStance Health Group (LFST) has drawn fresh investor attention after recent trading data showed the stock up over the past month and past 3 months. This move is prompting closer scrutiny of its mental health services business.
At a share price of $12.73, LifeStance Health Group has posted a 30 day share price return of 22.76% and a 90 day share price return of 71.79%. The 1 year total shareholder return of 137.06% points to strong recent momentum building from a lower multi year base.
Compare LifeStance Health Group’s momentum with a hand picked list of solid balance sheet and fundamentals (52 results) to see how other financially robust stocks have been trading recently.
After such a sharp reset in sentiment around LifeStance Health Group, the focus now shifts to price. Do the current valuation markers still offer an appealing trade off between risk and potential reward for new buyers?
Most Popular Narrative: 1.3% Undervalued
The most followed narrative currently estimates fair value for LifeStance Health Group at $12.90, which sits slightly above the last close at $12.73. That small gap has drawn attention to the specific growth and margin assumptions sitting underneath the model.
The continued and accelerating demand for mental health services in the U.S., driven by increasing public awareness and access to insurance coverage, is expected to expand LifeStance’s addressable market and support sustained double-digit revenue growth in the coming years. The ongoing migration of patients from cash-pay to commercial insurance, along with policy initiatives supporting mental health parity, positions LifeStance to benefit from more stable reimbursement streams and higher patient volumes, thus boosting revenue predictability and growth.
Read the complete narrative. Read the complete narrative.
Want to understand why this narrative gives LifeStance Health Group only a slight discount to fair value? The story leans heavily on multi year revenue compounding, a step up in profit margins and a valuation multiple that still assumes premium earnings power. The crucial details are in how fast earnings scale relative to that richer future multiple and how long those conditions are assumed to hold.
The fair value estimate of $12.90 in this narrative is built off projected revenue growth, an uplift in profit margins and a discount rate of 7.24%. It also relies on a future earnings profile that uses a P/E multiple well above broader US Healthcare levels, alongside expectations for share count reduction and ongoing profit expansion. Result: Fair Value of $12.90 (UNDERVALUED)
